A-1331852 greatly potentiated regorafenib toxicity in Hep3B and HepG2 cells as measured in MTT assays after 16 h (Figure 2A,B), while BCL-2 depletion with ABT-199 was not effective in increasing regorafenib action in the same hepatoma cell lines (Figure 2C,D). Here, BCL2 is linked to hepatocellular carcinoma.